QuantHealth raises $45m Series B for AI clinical trial simulation

What QuantHealth does

Drug developers use the platform to test trial protocols, refine inclusion and exclusion criteria and model commercial outcomes before enrolling patients. It draws on real-world data and predictive analytics across more than 30 therapeutic areas, including oncology, cardiometabolic and inflammatory diseases.

Chief executive and co-founder Orr Inbar said clinical development decisions are still largely made through real-world iteration, and that with simulation teams can evaluate clinical and commercial decisions before enrolling a single patient. He told Calcalist the company is fundamentally changing that model.

HIT Consultant cited the problem the product targets: more than 90% of clinical-stage drugs fail, and roughly 75% of clinical failures stem from efficacy or safety problems.

HIT Consultant reported that the company's tools are embedded in clinical development workflows at pharmaceutical companies, and that it also models commercial outcomes, not only trial design.

Claims and customers

The company says the platform has run more than 600 simulated trials across 30 indications, with predictive accuracy of up to 90%, and that it is embedded in the clinical development workflows of 12 of the top 20 pharmaceutical companies. These are company claims, and no customers were named.

Calcalist reported that the company was founded in 2020 and has about 85 employees, with offices in New York and Tel Aviv.

The team

Inbar previously worked at ConcertAI. Calcalist named Arnon Horev as co-founder, who earlier led business operations at Nucleai and managed marketing and sales at EarlySense.

The articles did not give amounts or dates for the company's earlier funding rounds.

Inbar described the shift away from running trials and adjusting at high cost as the change the company wants to bring about, according to Calcalist.

What the money is for

HIT Consultant reported that the funds will go to developing next-generation AI models and strengthening scientific validation, expanding proprietary datasets, covering more than 40 disease indications and broadening products across clinical and commercial development. QuantHealth will also grow its client-engagement and go-to-market teams.

The round is notable for the presence of Sanofi Ventures, the venture arm of a large drug developer, among the investors, although the sources did not say whether it is also a customer.

Sanofi was also named by Calcalist among QuantHealth's earlier investors, together with Accenture Ventures. The reports did not state a revenue figure.